DRMA

Business Context and Reporting Period

Dermata Therapeutics, Inc. (DRMA) is a clinical-stage biotechnology company focused on developing pharmaceutical candidates for medical and aesthetic skin conditions, primarily utilizing its proprietary Spongilla technology. The company reported for the quarterly period ended June 30, 2025. As of this date, the company had no commercial revenue and remains in a pre-revenue stage, relying on equity financing to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by approximately $1.97 million year-over-year for the six-month period. This was primarily driven by a $1.71 million reduction in R&D expenses, attributed to the completion of enrollment for the XYNGARI Phase 3 STAR-1 clinical trial in late 2024.
• Capital Raising: The company significantly increased its cash position through two major financing events in the first half of 2025:
  • January 2025 PIPE: Raised approximately $2.2 million net proceeds.
  • March 2025 Warrant Inducement: Raised approximately $5.7 million net proceeds by inducing holders to exercise existing warrants at a reduced price in exchange for new warrants.
• Share Count: Outstanding common shares increased from 251,725 at year-end 2024 to 637,757 as of June 30, 2025, due to the PIPE financing and warrant exercises. Note: Financial statements reflect a retroactive 1-for-10 reverse stock split effected in August 2025.

Outlook, Risks, and Management Commentary

• Clinical Progress: In March 2025, the company announced positive topline results for the XYNGARI Phase 3 STAR-1 trial for acne, meeting all co-primary endpoints. Management is evaluating next steps for the required second Phase 3 trial (STAR-2).
• Liquidity and Going Concern: As of June 30, 2025, cash balances of $6.5 million are projected to fund operations into the second quarter of 2026. The filing explicitly states that these factors raise substantial doubt about the company's ability to continue as a going concern for one year following the issuance of the financial statements.
• Supply Chain Risk: The company relies on an exclusive supply agreement with a Russian entity for Spongilla raw material. While current inventory is sufficient for two Phase 3 studies, future sanctions or export controls could disrupt supply.
• Collaboration: Entered a clinical trial collaboration with Revance Therapeutics in January 2025 to evaluate XYNGARI combined with Daxxify for hyperhidrosis.
• Listing Status: The company received a Nasdaq delisting notice regarding minimum bid price compliance in May 2025. A 1-for-10 reverse stock split was approved by shareholders in July 2025 and effected in August 2025 to regain compliance.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the projection that current cash ($6.5M) will sustain operations only until Q2 2026, necessitating immediate future capital raises.
• STAR-2 Trial Funding: Confirm the estimated cost and timeline for the second Phase 3 trial (STAR-2) required by the FDA, as this is the primary near-term capital requirement.
• Supply Chain Resilience: Assess the specific risks associated with the Russian raw material supplier and the sufficiency of current inventory levels against potential new sanctions.
• Dilution Impact: Review the impact of the recent warrant inducements and PIPE financing on shareholder dilution, noting the significant increase in outstanding shares and warrants.
• Nasdaq Compliance: Monitor the effectiveness of the 1-for-10 reverse stock split in maintaining the company's listing on the Nasdaq Capital Market.